Hypoxia-inducible factor-1α (HIF-1α) is a
transcription factor that triggers adaptive responses upon low
oxygen conditions and plays a crucial role in
cancer metabolism and
therapy resistance.
Tetrathiomolybdate (TM), a
therapy option for
copper overload disorder, has also been shown to be capable of limiting
tumor angiogenesis, although its underlying mechanism remains unclear. Using ovarian and
endometrial cancer cell lines, we observed that TM downregulates HIF-1α
protein levels and HIF-transcriptional targets involved in
tumor angiogenesis and glycolysis, but did not affect HIF-1α
protein synthesis. TM-mediated HIF-1α downregulation was suppressed when HIF-
prolyl hydroxylase activity was pharmacologically inhibited using
deferoxamine or dimethyloxaloylglycine, and also when the
oxygen-dependent degradation domains of HIF-1α, which are responsible for the interaction with HIF-
prolyl hydroxylase, were deleted. These findings suggest that TM causes HIF-1α downregulation in a HIF-
prolyl hydroxylase-dependent manner. Our studies showed that TM inhibits the activity of the
copper-dependent mitochondrial complex IV and reduces mitochondrial respiration, thereby possibly increasing
oxygen availability, which is crucial for HIF-
prolyl hydroxylase activity.
Pimonidazole staining also showed that TM elevates
oxygen tension in hypoxic cells. Our studies provide mechanistic evidence for TM-mediated HIF-1α regulation and suggest its therapeutic potential as a method of blocking angiogenesis in ovarian and endometrial
tumors.